共 154 条
[1]
Yarden Y(2001)Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127-137
[2]
Sliwkowski MX(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177-182
[3]
Slamon DJ(2007)Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 977-984
[4]
Clark GM(2007)Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity Expert Opin Biol Ther 7 257-268
[5]
Wong SG(2005)Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265-4274
[6]
Levin WJ(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-2743
[7]
Ullrich A(2004)PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117-127
[8]
McGuire WL(2005)TGFalpha expression impairs Trastuzumab-induced HER2 downregulation Oncogene 24 3002-3010
[9]
Valabrega G(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
[10]
Montemurro F(2007)Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol 25 5410-5417